JUBLINGREA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.2
| Stock Code | JUBLINGREA | Market Cap | 10,176 Cr. | Current Price | 638 ₹ | High / Low | 852 ₹ |
| Stock P/E | 36.7 | Book Value | 166 ₹ | Dividend Yield | 0.78 % | ROCE | 12.4 % |
| ROE | 10.9 % | Face Value | 1.00 ₹ | DMA 50 | 661 ₹ | DMA 200 | 668 ₹ |
| Chg in FII Hold | 0.34 % | Chg in DII Hold | 0.76 % | PAT Qtr | 105 Cr. | PAT Prev Qtr | 69.4 Cr. |
| RSI | 42.3 | MACD | -13.9 | Volume | 3,78,893 | Avg Vol 1Wk | 3,54,653 |
| Low price | 535 ₹ | High price | 852 ₹ | PEG Ratio | 12.4 | Debt to equity | 0.28 |
| 52w Index | 32.4 % | Qtr Profit Var | 17.1 % | EPS | 16.8 ₹ | Industry PE | 28.7 |
📊 Jubilant Ingrevia (JUBLINGREA) shows moderate fundamentals. The company trades at a P/E of 36.7 compared to industry PE of 28.7, suggesting premium valuation. ROE (10.9%) and ROCE (12.4%) are modest, while EPS of ₹16.8 supports earnings visibility. Dividend yield of 0.78% adds minor income appeal. Debt-to-equity is low at 0.28, ensuring financial stability. Quarterly PAT rose to ₹105 Cr. from ₹69.4 Cr., showing growth, but PEG ratio of 12.4 indicates severe overvaluation relative to growth. Technicals are weak with RSI 42.3 and negative MACD -13.9, suggesting bearish momentum.
💰 Ideal Entry Price Zone: ₹600 – ₹630, near DMA 50 (₹661) and DMA 200 (₹668), offering better valuation comfort below highs.
📈 Exit Strategy / Holding Period: For existing holders, a medium-term horizon (2–3 years) is advisable. Exit if valuations remain stretched (P/E > 40) without earnings growth or if ROE/ROCE stagnate. Long-term holding is only justified if profitability stabilizes and efficiency metrics strengthen.
Positive
- ✅ Fair [P/E ratio](ca://s?q=PE_ratio_explained) of 36.7 vs industry PE of 28.7.
- ✅ Strong quarterly [PAT](ca://s?q=PAT_explained) growth from ₹69.4 Cr. to ₹105 Cr. (+17.1%).
- ✅ Low [debt-to-equity](ca://s?q=Debt_to_equity_ratio) ratio of 0.28 ensures financial stability.
- ✅ Dividend yield of 0.78% provides minor income support.
Limitation
- ⚠️ High [PEG ratio](ca://s?q=PEG_ratio_explained) of 12.4 indicates overvaluation relative to growth.
- ⚠️ Modest [ROE](ca://s?q=Explain_ROE) (10.9%) and [ROCE](ca://s?q=Explain_ROCE) (12.4%).
- ⚠️ Weak technicals with [RSI](ca://s?q=RSI_indicator) at 42.3 and negative [MACD](ca://s?q=MACD_indicator) -13.9.
Company Negative News
- 📉 Valuation levels remain stretched compared to industry peers.
- 📉 Institutional sentiment weakened with decline in [FII holding](ca://s?q=FII_holdings) (-0.34%).
Company Positive News
- 📈 Quarterly [profit growth](ca://s?q=Profit_growth_analysis) (+17.1%) shows operational improvement.
- 📈 Increase in [DII holding](ca://s?q=DII_holdings) (+0.76%) reflects domestic institutional support.
Industry
- 🌐 Specialty chemicals sector outlook remains positive with rising demand in pharma and agro segments.
- 🌐 Industry PE at 28.7 highlights Jubilant Ingrevia’s premium valuation.
Conclusion
🚀 Jubilant Ingrevia is moderately strong with low debt and improving profitability, but faces valuation concerns and modest efficiency metrics. Entry is attractive in the ₹600–₹630 zone. Medium-term investors should hold for 2–3 years, with exit if valuations remain stretched or fundamentals fail to improve.